aibioVyome reports first quarter 2026 results and an in-licensing agreement
Tickers HIND
Vyome reported a net loss attributable to common shareholders of approximately $963,000 for the quarter ended March 31, 2026, and cash of approximately $8.8 million, while announcing an in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise.
Key facts
- Company
- Vyome Holdings, Inc. (NASDAQ: HIND)
- News type
- Company Updates
- Primary source
- Vyome Holdings, Inc. 8-K (2026-05-29)
Vyome Holdings, Inc. reported first quarter 2026 results and a corporate update in a press release dated May 28, 2026. The release was furnished in a Form 8-K filed May 29, 2026. It covers the quarter ended March 31, 2026.
The company said it had approximately $8.8 million in cash and cash equivalents at March 31, 2026, compared with approximately $5.0 million at December 31, 2025. Total assets were approximately $10.2 million and total stockholders' equity was approximately $8.0 million at March 31, 2026. For the quarter, total operating expenses were approximately $1.1 million, including approximately $666,000 in research and development and approximately $478,000 in selling, general, and administrative expenses. The net loss attributable to common shareholders was approximately $963,000, or approximately $0.15 per basic and diluted share.
The in-licensing agreement
Vyome said it entered into a strategic in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets. The release describes the structure as capital-light, with payments due at commercialization, and says development will use non-dilutive pathways. The release gives the global market as about $57B, citing a Research and Markets report.
Regulatory and clinical progress
The release says Vyome made regulatory submissions to the FDA related to readiness for a pivotal development program for VT-1953. Those submissions include discussions on manufacturing, toxicology, pharmacokinetic requirements and clinical development considerations. The company also filed an application for orphan drug designation for VT-1953. It said it presented positive VT-1953 Phase 2 clinical study data at the American Association for Cancer Research (AACR) 2026 meeting, and that it continued scientific and translational work on VT-1908.
Chief executive Venkat Nelabhotla said the company continues to advance VT-1953 "toward pivotal-stage readiness while maintaining a strong focus on disciplined execution, regulatory engagement, manufacturing preparedness, and financial stewardship." The release says the company continues to believe VT-1953 addresses a major unmet need in malignant fungating wounds, a condition the release describes as having no FDA-approved therapies specifically addressing it.
Capital structure
The release recalls that Vyome sold 1,089,545 common shares on January 27, 2026, for approximately $5.29 million in gross proceeds, at an average price of $5.00 per share. It says that price was a 59.2% premium to the prior day's closing price, with total dilution to existing shareholders of approximately 15%. The company describes its capital structure as clean and disciplined, with no debt or preferred stock.
The business and recent financials
The company's 10-K, filed March 18, 2026, describes VT-1953 as a topical gel being developed for malignant fungating wounds in advanced cancer. The filing calls VT-1953 a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator. Its pharmaceutical revenue comes from two topical anti-fungal products sold in India under a Sun Pharma Laboratories Limited license.
The XBRL data show revenue of $319,714 for fiscal 2025, against $256,944 for 2024, and a net loss of $10.3 million for 2025, against $1.4 million for 2024. Research and development expense was $588,258 in 2025, against $285,391 in 2024.
What the release does not show
The headline claims are the company's own. The release gives no figures for the Phase 2 data it calls positive, and the 10-K describes that study as investigator-initiated. VT-1953 has no pivotal trial design agreed with the FDA: the company says only that it submitted proposals for guidance and an orphan drug application. The 10-K said discussions on a pivotal Phase 3 design were planned for the first half of 2026, and the release does not say whether they have taken place.
The JAK inhibitor deal names no upfront fee, milestones or royalty rate, and the roughly $57B market figure comes from a third-party report, not from anything Vyome has developed. The release gives no development stage for the two assets. The company says it has no debt and no toxic financing, but it also sold shares at a time when its 2025 net loss was $10.3 million and cash used in operations was $3.7 million. Revenue was $319,714 for 2025, from antifungal products sold in India.